Thus, SLC34A2 expression may be a potential marker for malignancy of BC and an intervention target for treatment, that is, it implies that patients with high expression of SLC34A2 may need chemoradiation or molecular target therapy for tumor control after radical cystectomy, whereas those with low expression of SLC34A2 can avoid unnecessary treatments except for surgery. Here, SLC34A2 is linked to breast cancer.